Methods for selecting and treating cancer with FGFR3 inhibitors

A method of assaying a sample obtained from a human patient suffering from cancer, the method comprising measuring a nucleic acid expression level of each biomarker in a plurality of biomarkers in the sample obtained from the human patient suffering from cancer using an amplification, hybridization and/or sequencing assay, wherein the plurality of biomarkers consists of only apoptotic chromatin condensation inducer 1 (ACIN1), aminoacylase 1 (ACY1), TLE family member 5, transcriptional modulator (AES), Ankyrin repeat domain-containing protein 50 (ANKRD50), Annexin A10 (ANXA10), adaptor related protein complex 1 subunit gamma 2 (APIG2), apolipoprotein L1 (APOL1), Rho Guanine Nucleotide Exchange Factor 10 Like (ARHGEF10L), BTB domain containing 16 (BTBD16), chromosome 2 open reading frame 66 (C2orf66), carbonyl reductase 4 (CBR4), chloride channel accessory 4 (CLCA4), CDC like kinase 1 (CLK1), cytochrome P450 family 3 subfamily A member 5 (CYP3A5), neuronal vesicle trafficking associated 1 (D4S234E), diacylglycerol kinase alpha (DGKA), diacylglycerol kinase theta (DGKQ), dehydrogenase/reductase 3 (DHRS3), EPH receptor B6 (EPHB6), fatty acid binding protein 6 (FABP6), family with sequence similarity 155 member B (FAM155B), fibroblast growth factor receptor 3 (FGFR3), GIPC PDZ domain containing family member 1 (GIPC1), gastric inhibitory polypeptide receptor (GIPR), G protein-coupled receptor 108 (GPR108), histone deacetylase 10 (HDAC10), homeobox B3 (HOXB3), homeobox B4 (HOXB4), homeobox B6 (HOXB6), homeobox D4 (HOXD4), JMJD7-PLA2G4B readthrough (JMJD7-PLA2G4B), keratin associated protein 5-10 (KRTAP5-10), LIM domain binding 1 (LDB1), lipoprotein (a) (LPA), lysophosphatidylcholine acyltransferase 4 (LPCAT4), LUC7 like (LUC7L), mannosidase alpha class 2C member 1 (MAN2C1), methyl-CpG binding domain protein 6 (MBD6), microsomal glutathione S-transferase 2 (MGST2), MAPK interacting serine/threonine kinase 2 (MKNK2), membrane metalloendopeptidase like 1 (MMEL1), NAD synthetase 1 (NADSYN1), NDUFA4 mitochondrial complex associated like 2 (NDUFA4L2), nuclear RNA export factor 3 (NXF3), olfactory receptor family 9 subfamily K member 2 (OR9K2), protein interacting with PRKCA 1 (PICK1), phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), phospholipase C delta 3 (PLCD3), pleckstrin homology domain containing, family H (with MyTH4 domain) member 3 (PLEKHH3), plexin B3 (PLXNB3), pre-mRNA processing factor 40 homolog B (PRPF40B), retinoic acid induced 1 (RAI1), ras homolog family member T2 (RHOT2), semaphorin 4B (SEMA4B), SH3 domain binding protein 1 (SH3BP1), SMAD family member 3 (SMAD3), sorting nexin 1 (SNX1), SRY-box transcription factor 15 (SOX15), spermatogenesis associated 20 (SPATA20), SAM pointed domain containing ETS transcription factor (SPDEF), SPOC domain containing 1 (SPOCD1), slingshot protein phosphatase 3 (SSH3), synaptotagmin like 1 (SYTL1), transcriptional adaptor 2B (TADA2B), trefoil factor 1 (TFF1), transmembrane BAX inhibitor motif containing 4 (TMBIM4), transmembrane serine protease 4 (TMPRSS4), toll interacting protein (TOLLIP), TraB domain containing (TRABD), TRIO and F-actin binding protein (TRIOBP), tetraspanin 14 (TSPAN14), translocator protein (TSPO), tubulin gamma 2 (TUBG2), tubulin gamma complex associated protein 6 (TUBGCP6), thioredoxin domain containing 17 (TXNDC17), UDP glucuronosyltransferase family 2 member B28 (UGT2B28), Wnt family member 7B (WNT7B), zinc finger and BTB domain containing 7A (ZBTB7A), zinc finger protein 385A (ZNF385A) and zinc finger protein 692 (ZNF692).